Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Itepekimab · REGN-3500, SAR-440340

Monoclonal antibody · developed by REGENERON PHARMACEUTICALS

Phase 3 Most advanced trial
REGN Developer

What is Itepekimab?

Itepekimab (REGN3500, SAR-440340) is a subcutaneously administered solution in a prefilled syringe. It is studied in chronic rhinosinusitis with nasal polyps.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
REGN-3500, SAR-440340
Drug type
Monoclonal antibody
Therapy area
Ear, nose & throat
Developer
REGENERON PHARMACEUTICALS (REGN)
Also in trials of
SNY
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
WV9KZ9PS1A

Conditions studied

Chronic Rhinosinusitis With Nasal Polyps

More from REGENERON PHARMACEUTICALS

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the REGN page.

Follow REGN, the company behind Itepekimab

See REGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.